Summary
Thermo Fisher Scientific Inc. (TMO) reported strong revenue growth in 2005, driven by significant acquisitions and organic demand across its key segments. The company's strategy of augmenting internal growth with strategic acquisitions has bolstered its presence, particularly in the Life and Laboratory Sciences segment, which saw a substantial increase in sales due to the acquisition of Kendro. The Measurement and Control segment also experienced growth, benefiting from demand in industrial and environmental applications. While the company experienced higher operating income, its operating income margin saw a slight decrease due to increased amortization expenses from acquisition-related intangible assets. Management is focused on integrating acquired businesses to realize synergies and improve productivity. The company maintains a solid financial position with sufficient liquidity and manages its market risks through operational activities and hedging strategies.
Key Highlights
- 1Revenue increased by 19% to $2.63 billion in 2005, driven by a 15% contribution from acquisitions and net divestitures, alongside a 4% increase in organic sales.
- 2The Life and Laboratory Sciences segment experienced a significant revenue jump of 25%, largely due to the acquisition of Kendro Laboratory Products and other strategic acquisitions, complemented by broad-based demand and new product introductions.
- 3The Measurement and Control segment saw a 6% revenue increase, primarily from higher demand in industrial and environmental/security applications.
- 4Operating income grew to $263.5 million, though the operating income margin slightly decreased to 10.0% from 10.8% in the prior year, primarily due to $54.8 million in increased amortization of acquisition-related intangible assets.
- 5Thermo Fisher Scientific completed several key acquisitions in 2005, including Kendro Laboratory Products ($836.6 million), Ionalytics Corporation ($24.7 million), Rupprecht and Patashnick Co., Inc. ($31.0 million), and Niton LLC ($40.9 million), significantly expanding its capabilities and market reach.
- 6The company continues to invest in research and development, with R&D expenses totaling $152.8 million in 2005, a 13% increase from the previous year.
- 7Backlog increased to $528.1 million at year-end 2005, up from $467.0 million in 2004, indicating strong future demand, particularly in the Life and Laboratory Sciences segment.